Abnova Taiwan 4133.TW · TWD

Its shares trade on Taiwan Stock Exchange under the ticker 4133.TW. It has been listed since 27 May 2008. In the fiscal year to 31 December 2025, it reported revenue of TWD 351.3m and a net loss of TWD 1.1m. At that date it held total assets of TWD 1.33bn and shareholders' equity of TWD 1.26bn.

Abnova Taiwan Corp. is engaged in researching, developing, manufacturing and selling antibodies. The company is headquartered in Taipei City, Taipei. The company went IPO on 2008-05-27. The firm's products mainly include monoclonal antibodies, polyclonal antibodies, protein fragments, full-length proteins, active proteins, antibody pairs, fluorescence in situ hybridization probe and others. The firm's monoclonal and polyclonal antibodies are primarily applied in medical testing reagents, agricultural testing, industrial purification, medical treatment and other fields. Its proteins are mainly applied in medical testing reagents, agricultural testing, medical treatment, protein engineering and other fields. Its products are mainly traded in Taiwan, Americas and Europe.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Wilber HuangChairman of the Board, since 2002TWD 12.7m
• Ms. Peiru JiGeneral Manager
• Yiling DongCorporate Governance Officer
• Yaping ZhangHead of Finance & Accounting
• Mr. Yuehong ChenDirectorTWD 281,000
• Ms. Fangwen LiDirectorTWD 281,000
• Ms. Qijing QiuDirectorTWD 281,000
• Anna ChaIndependent Director
• Mr. Jiaxun LinIndependent DirectorTWD 401,000
• Mr. Jinjun SuIndependent DirectorTWD 401,000
• Mr. Shaode YeIndependent DirectorTWD 401,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.